Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin and Natco Pharma have signed an agreement to jointly commercialize the generic version of Tykerb (Lapatinib ditosylate) tablets of GlaxoSmithKline (GSK).
Subscribe to our email newsletter
Natco had earlier submitted an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market GSK’s generic version of Tykerb 250mg tablets.
Tykerb tablets are indicated as a treatment for certain types of advanced or metastatic breast cancer and are used in combination with another medicine (capecitabine or letrozole).
Tykerb is a protein-tyrosine kinase inhibitor which works by preventing the growth of cancer cells.